Form 4: Intra-Cellular Therapies CEO Sharon Mates Sells Shares to Cover Tax Obligations
SEC Form 4
Sharon Mates, the Chairman, President, and CEO of Intra-Cellular Therapies, Inc., sold shares of common stock between March 7 and March 11, 2024, to cover tax liabilities arising from the vesting of restricted stock units.
Summary
- Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, sold shares of the company's common stock between March 7 and March 11, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2023, and amended on June 9, 2023.
- A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- On March 7, 2024, she sold 31,958 shares at $66.38 and 8,754 shares at $66.93.
- On March 10, 2024, 20,565 restricted stock units converted into common stock.
- On March 11, 2024, she sold 14,541 shares at $64.8, 4,128 shares at $65.9, 1,590 shares at $66.81 and 306 shares at $67.33.
- Following these transactions, Mates directly owns 1,050,309 shares of Intra-Cellular Therapies common stock and 20,566 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an executive. The use of a 10b5-1 plan suggests the sales were pre-planned and not indicative of any negative sentiment towards the company's prospects. Therefore, the sentiment is neutral.
Industry Context
Executive stock sales are a common occurrence, often related to personal financial planning or tax obligations. The use of a pre-arranged 10b5-1 trading plan suggests the sales were planned in advance and not based on insider information.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small volume of shares sold compared to the total outstanding shares.
- The sales do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-03-10 | Reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 2023-03-14 | Date of adoption of Rule 10b5-1 trading plan. |
| 2023-06-09 | Date of amendment of Rule 10b5-1 trading plan. |
| 2024-03-07 | Sale of 31,958 shares at $66.38 and 8,754 shares at $66.93. |
| 2024-03-10 | Conversion of 20,565 restricted stock units into common stock. |
| 2024-03-11 | Sale of 14,541 shares at $64.8, 4,128 shares at $65.9, 1,590 shares at $66.81 and 306 shares at $67.33. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.